Atara Biotherapeutics, Inc. Share Price & Technical Analysis
ATRA · $9.80 (+4.93%)
Healthcare / Biotechnology
$9.80
+4.93%
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and internationally. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as oth…
Price chart
Seasonality
May has 1 positive and 4 negative years (last 5 years shown)
104% return in May, -22% avg return in past 3 year May month.
27% return in 2026, -14% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -72% | 6% | -10% | -2% | 104% | – | – | – | – | – | – | – | 27% |
| 25 | -33% | -18% | -14% | 29% | -2% | -1% | 51% | 6% | 19% | 4% | 1% | 22% | 64% |
| 24 | 14% | 25% | -9% | -4% | -21% | -39% | 15% | -25% | 8% | 10% | 34% | 11% | 20% |
| 23 | 53% | -20% | -28% | -5% | -43% | 4% | 35% | -35% | 1% | -15% | -50% | -20% | -125% |
| 22 | -4% | -16% | -23% | -32% | -19% | 48% | -61% | 33% | -6% | 19% | -5% | -28% | -95% |
Monthly return % by calendar month · historical pattern, not a forecast
Neutral · Emerging · Strong
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and internationally. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases. It also develops ATA3219, an allogeneic CAR T targeting CD19 intended to target B-cell malignancies and autoimmune diseases. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$84.61M
P/E ratio
3.87
52W high
$19.14
52W low
$3.92
Volume
1,25,047
Beta
-0.29
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Atara Biotherapeutics, Inc. share price today?
- Atara Biotherapeutics, Inc. (ATRA) last traded around $9.80 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does ATRA have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for ATRA. Download the app for real-time alerts.
- How can I analyze Atara Biotherapeutics, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.